Please login to the form below

Not currently logged in
Email:
Password:

ABPI names Amgen’s UK head as president

John Kearney replaces Pfizer’s Jonathan Emms

John Kearney, ABPIThe Association of the British Pharmaceutical Industry (ABPI) has appointed John Kearney as its new president, effective from April 24.

Kearney has over 35 years of experience in the pharma industry and currently holds the position of general manager UK and Ireland at Amgen.

He replaces Jonathan Emms, who is stepping down as president as he is leaving his role as head of Pfizer's UK business to a new role with the company in the US.

Commenting on his appointment, Kearney said: “I am delighted to be building on the recent leadership of Jonathan Emms, at a time when the pharmaceutical industry as a whole is delivering such a high quality and quantity of new science and treatment innovations.

“I look forward to playing my part in ensuring those innovations are able to make a real difference in the funding and provision of health services, in the outstanding work of healthcare professionals in the UK, and – ultimately – to patients.”

Kearney held UK and international roles at GlaxoSmithKline and international roles at Pfizer, before joining Amgen in 2007. He has been on the board of the ABPI since 2008 where he has worked on a number of key initiatives, including leading its pricing team in negotiations with the Department of Health to secure the 2014 PPRS.

Stephen Whitehead, CEO of the ABPI, added: “I am delighted to be working alongside John as president. His unique experience and expertise across the industry will be crucial as he leads the ABPI and the UK pharmaceutical industry through the opportunities and challenges in 2015.”

10th February 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget....
Innovative approaches in the treatment of multiple sclerosis
Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon....

Infographics